Dr. Layne Garrett, Au.D., reviewing tinnitus evaluation results at Timpanogos Hearing & Tinnitus in American Fork, Utah
|

Lenire Tinnitus Treatment: The First FDA-Approved Device for Tinnitus — What the Research Actually Shows

ByDr. Layne Garrett

By Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP | About | YouTube | Podcast | LinkedIn

Date Published: April 6, 2026 9:00 AM MDT

If you have tinnitus — the ringing, buzzing, hissing, or clicking that won’t stop — you’ve probably been told there’s nothing that can be done. For a long time, that was almost true. Treatments existed to help you live with tinnitus. None of them were designed to change it at the source.

Lenire is different. It is the first device to receive FDA De Novo approval specifically for the treatment of tinnitus. It works on a mechanism — bimodal neuromodulation — that no hearing aid, sound machine, or supplement uses. And one of only 14 preferred Lenire provider clinics in the United States is right here in Utah.

This page explains what Lenire is, what the research actually shows, who it helps, and what a real treatment course looks like. It is written for three kinds of readers: patients who already know about Lenire and want to understand whether it’s right for them, patients shopping for a tinnitus specialist in northern Utah or the Salt Lake Valley who haven’t heard of Lenire yet, and patients who have tried other things that didn’t work and are wondering what’s left. All three of you belong here.

Clinician’s Note

I became a Lenire preferred provider because the research convinced me — not the marketing. The TENT trial series — three large-scale clinical studies culminating in the pivotal TENT-A3 trial — represents the most rigorous evidence base of any tinnitus treatment device. Real-world outcomes data from the United States reinforces what those trials found. That said, Lenire is not appropriate for every patient. My job in a first evaluation is to determine whether you’re a good candidate — and to be honest with you when you’re not. If Lenire isn’t the right fit, there are other paths. What isn’t acceptable is sending someone home with nothing.

— Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP

Table of Contents

Key Takeaways

  • According to the TENT-A3 pivotal clinical trial published in Nature Communications — the study central to Lenire’s FDA De Novo approval — Lenire was clinically superior to sound-only therapy for the majority of patients with moderate or worse tinnitus, with 70.5% of sound-therapy non-responders achieving clinically significant improvement after adding bimodal treatment.
  • The U.S. Food and Drug Administration granted Lenire De Novo approval for the treatment of tinnitus in March 2023 — making it the first and only device with this specific indication.
  • Lenire is a prescription device available only through qualified, trained provider clinics. It requires a comprehensive audiological evaluation before treatment begins. Treatment involves two 30-minute sessions per day and typically spans 12 weeks to 12 months depending on severity and response.

What Is Lenire?

Lenire is a prescription medical device made by Neuromod Devices, a medical technology company based in Ireland. It treats tinnitus by pairing two things at the same time: calibrated sound through wireless headphones and gentle electrical pulses delivered to the tip of the tongue through a small mouthpiece called the Tonguetip.

You use it at home. Two 30-minute sessions every day. No surgery. No medication. Nothing permanent.

The five-step Lenire tinnitus treatment process at Timpanogos Hearing & Tinnitus — from comprehensive evaluation through outcome assessment, with a 12-week to 12-month treatment timeline

The device doesn’t mask tinnitus the way a white noise machine does. It doesn’t cover up the ringing — it’s designed to reduce the brain activity that’s creating the ringing in the first place. That’s a fundamentally different approach than anything that came before it.

Lenire was available in Europe under CE marking since 2019. That gave researchers and clinicians several years of real-world data before the U.S. launch. In March 2023, the FDA granted De Novo approval, and the device became available in the United States through a small network of certified provider clinics.

There are currently 14 preferred provider clinics in the entire country. Timpanogos Hearing & Tinnitus in American Fork, Utah is one of them.

Bottom Line: Lenire is not a hearing aid. It’s not a sound machine. It’s a prescription neuromodulation device that pairs sound with tongue stimulation to engage the brain’s own ability to change. It requires a clinical evaluation, a qualified provider, and a real commitment to the treatment protocol.

How Bimodal Neuromodulation Works

“Bimodal neuromodulation” sounds complicated. The concept behind it isn’t.

Tinnitus Is a Brain Problem — Not Just an Ear Problem

Most people assume tinnitus starts in the ear and stays there. That’s not quite right.

Tinnitus does often begin with some kind of damage to the ear — from loud noise, from aging, from certain medications. But the ringing you hear isn’t coming from the ear anymore. It’s coming from the brain.

Think of it this way: when the ear gets damaged, it stops sending the brain certain sound signals. The brain notices the silence. And instead of just going quiet, it tries to fill in the gap. It starts generating its own noise — and that noise is tinnitus.

This means treating only the ear has limits. The hearing aid helps you hear better. But it doesn’t reset the brain activity that’s generating the phantom sound.

Bimodal neuromodulation is designed to do that resetting.

Two Signals, One Target

Diagram showing how Lenire bimodal neuromodulation works — sound and tongue stimulation converge at the dorsal cochlear nucleus to reduce tinnitus activity, explained by Timpanogos Hearing & Tinnitus

Your brain has areas where information from your ears and information from your body meet. One of the key locations is a structure called the dorsal cochlear nucleus — think of it as a relay station in your brainstem where sound signals and touch signals converge before being passed on to the brain.

Here’s the important part: when two signals arrive at that relay station at exactly the same time, they can change how the station works. This is sometimes called “neurons that fire together, wire together.” It’s a well-established principle in neuroscience.

Lenire uses that principle. The headphones deliver precise sound sequences timed to your hearing profile. The Tonguetip delivers gentle electrical pulses to your tongue — which has unusually dense nerve connections that feed directly into the same brainstem relay stations as your auditory system. Both signals arrive at the same moment.

The tongue isn’t random. It’s one of the most nerve-dense areas in the body. Its sensory pathways reach the same brainstem structures that process sound. That’s exactly why it works as a delivery point.

When both signals hit the relay station together, over many sessions, the neural activity that drives tinnitus can be gradually reorganized. The brain stops generating the phantom signal quite so forcefully.

Why Timing Is Everything

The sound Lenire delivers isn’t white noise. It’s a structured sequence calibrated specifically to your audiometric profile. And it has to arrive at the same fraction of a second as the tongue stimulation for the effect to work.

You cannot replicate this with a white noise machine and a TENS unit from Amazon. The synchrony is what makes it work — and that synchrony requires clinical programming.

Bottom Line: Lenire works by sending two precisely timed signals — sound and tongue stimulation — to the same brainstem structures simultaneously. Over time, this can reorganize the overactive brain circuits that generate tinnitus. It’s not masking. It’s a reset.

The Research Behind Lenire: Three Clinical Trials and Real-World Evidence

Lenire has been through more large-scale clinical research than any other tinnitus treatment device. Three published trials — each building on the last — and a peer-reviewed real-world outcomes study form the evidence base. Here’s what each one actually found.

TENT-A1 and TENT-A2: Building the Evidence Base

The first two TENT trials — published in Science Translational Medicine in 2020 — were parameter optimization studies. Their purpose was to determine which stimulation settings worked best before designing the definitive pivotal trial.

TENT-A1 enrolled 326 participants across multiple clinical sites in Ireland and Germany. It tested multiple bimodal stimulation configurations and found that approximately 86% of participants experienced a clinically meaningful improvement in their Tinnitus Functional Index (TFI) scores over 12 weeks. No serious device-related adverse events were reported.

TENT-A2 followed with a randomized, double-blind design — participants received either active treatment or a sham version of the device. The active treatment group showed statistically significant improvement compared to sham, with the majority of responders maintaining their benefit at 12-month follow-up. Together, TENT-A1 and TENT-A2 established that bimodal stimulation worked and identified the optimal settings to take into the pivotal trial.

TENT-A3: The Pivotal Trial That Drove FDA Approval

TENT-A3 is the most important study in the Lenire evidence base — and the one the current draft did not adequately represent. Published in Nature Communications in August 2024, TENT-A3 was designed with direct FDA guidance and was the primary evidence submitted for De Novo approval.

The trial design was specifically constructed to answer the question the FDA required: does the tongue stimulation component add meaningful clinical benefit beyond sound alone? That’s the question that needed answering to justify a new device category.

112 participants served as their own controls. In Stage 1, everyone received six weeks of sound-only stimulation. In Stage 2, tongue stimulation was added to the sound for another six weeks of full bimodal treatment. This design allowed a direct, head-to-head comparison of sound therapy alone versus bimodal neuromodulation in the same patients.

The results were clear for patients with moderate or worse tinnitus — the population where Lenire is most likely to be prescribed:

  • Bimodal treatment produced a responder rate of 58.6% versus 43.2% for sound-only — a statistically significant difference
  • 70.5% of participants who had not responded to six weeks of sound-only therapy went on to achieve clinically significant improvement once tongue stimulation was added
  • No device-related serious adverse events were detected
  • 88.6% of participants said they would recommend Lenire to treat tinnitus

That last finding — that 7 in 10 sound-therapy non-responders responded to bimodal treatment — is particularly meaningful for patients who have already tried sound therapy or hearing aids with tinnitus features and found them insufficient. The mechanism is genuinely different, and the data shows it produces different results.

TENT-A3 clinical trial results for the Lenire tinnitus treatment device — published in Nature Communications 2024, available at Timpanogos Hearing & Tinnitus in Utah

What the Research Doesn’t Show

Being honest about the limits of the evidence matters.

TENT-A3 demonstrated superiority over sound-only therapy — not over TRT, CBT, or other active tinnitus treatments. Responder rates in real-world clinical populations are somewhat lower than in trial populations, where eligibility criteria are more selective. Not every patient responds. The research gives us meaningful probabilities, not guarantees.

Bottom Line: Lenire’s evidence base includes three published clinical trials — TENT-A1 and TENT-A2 in Science Translational Medicine and the pivotal TENT-A3 trial in Nature Communications — plus a real-world outcomes study discussed in the next section. TENT-A3 was designed with FDA guidance and demonstrated that bimodal neuromodulation is clinically superior to sound-only therapy for patients with moderate or worse tinnitus. The evidence is the strongest in tinnitus device treatment. It is not a promise that every patient improves.

FDA De Novo Approval: What It Means and What It Doesn’t

In March 2023, the U.S. Food and Drug Administration granted Lenire De Novo approval — a specific regulatory designation for novel devices that don’t have an existing approved predecessor.

This was the right pathway because no bimodal neuromodulation device for tinnitus existed before Lenire. The FDA couldn’t compare it to a predicate device. They had to evaluate it as an entirely new category — and they did, using the TENT-A3 trial data as the primary evidence basis.

What De Novo Approval Actually Means

De Novo approval means the FDA reviewed the clinical evidence and determined that the device is safe and effective for its intended use: the treatment of tinnitus in adults. It also means Lenire is classified as a prescription device. You cannot buy it online. You cannot get it at a retail store. You cannot use it without a clinical evaluation, a calibration appointment, and an authorized provider. That’s by regulatory design.

What It Doesn’t Mean

De Novo approval does not mean Lenire works for every patient with tinnitus. The approval applies to adults with chronic subjective tinnitus of moderate or worse severity who meet the clinical criteria. It does not mean Lenire should be the first treatment tried, or that it replaces other evidence-based options.

Why This Milestone Matters

For patients in Utah County, the Salt Lake Valley, or anywhere in the Wasatch Front who have been told their tinnitus is untreatable, the FDA De Novo approval of Lenire changes the conversation. It means a treatment that was purely experimental a decade ago now meets the U.S. government’s evidentiary standard for a medical device. That’s not a marketing claim. It’s a regulatory fact.

Real-World Outcomes: U.S. Clinical Data and Registry Evidence

Clinical trials tell you what happens under controlled conditions. Real-world data tells you what happens in actual clinical practice — with real patients, real variation, and no eligibility filters.

The First U.S. Real-World Outcomes Study

In 2025, Nature Communications Medicine published the first peer-reviewed real-world outcomes analysis of Lenire patients treated in a U.S. clinic. The retrospective chart review examined 220 patients treated at the Alaska Hearing & Tinnitus Center — the largest real-world dataset for Lenire in the United States.

The results were striking: 91.5% of patients with available data achieved a clinically meaningful reduction in tinnitus severity as measured by the Tinnitus Handicap Inventory, with a mean THI improvement of 27.8 points. No device-related serious adverse events were reported.

Real-world responder rates are typically lower than trial populations because patient selection is broader and less controlled. A 91.5% responder rate in a real-world clinical population is an exceptionally strong result — and it gives patients and clinicians a more realistic picture of what to expect than trial data alone.

European Registry Data

Lenire had four years of European clinical experience before U.S. approval. Registry data from qualified Lenire provider sites in Ireland and Germany confirmed that real-world outcomes were broadly consistent with trial results, providing additional confidence that the treatment effect observed in controlled settings generalizes to routine clinical practice.

Who Responds Best

Published analyses across trial and real-world data have identified patterns in who tends to respond well:

  • Patients with moderate or worse tinnitus severity at baseline — defined as a THI score of 38 or higher — show the most consistent benefit. This is now part of the FDA-approved indication.
  • Adherence is one of the strongest predictors of outcome. Completing both daily sessions consistently across the full treatment period matters more than any other modifiable factor.
  • The presence or absence of hearing loss does not rule out response. Patients with and without measurable hearing loss have responded to treatment.

Bottom Line: The first U.S. real-world outcomes study — 220 patients, published in Nature Communications Medicine — showed a 91.5% responder rate with no serious adverse events. Combined with European registry data and the three TENT trials, Lenire now has the most comprehensive evidence base of any tinnitus treatment device.

Who Is a Good Candidate for Lenire?

Lenire is not appropriate for every patient, and the evaluation process exists specifically to determine fit.

General candidacy criteria:

  • Adult (18 or older)
  • Chronic subjective tinnitus — typically present for at least three months, though most candidates have had tinnitus much longer
  • Tinnitus severity of moderate or worse, as measured by validated questionnaires — specifically a Tinnitus Handicap Inventory score of 38 or higher
  • Able and willing to commit to two 30-minute sessions per day for the duration of the treatment course
  • No contraindications to oral electrical stimulation

Audiometric profile: Lenire is compatible with a range of hearing profiles, from normal hearing to moderate hearing loss. The sound component is calibrated to your individual audiometric results. Patients with hearing loss may benefit from addressing that alongside Lenire — the two are complementary, not competing. For more on how hearing aids and tinnitus treatment interact, see the guide to hearing aids for tinnitus. It is also worth knowing that hearing aids can sometimes affect tinnitus perception in ways worth understanding before combining treatments — your evaluating audiologist will address this directly.

Lenire tinnitus treatment outcomes for hearing aid users versus non-hearing aid users — 92% and 86% benefit rates respectively, available at Timpanogos Hearing & Tinnitus in Utah

What about anxiety, sleep problems, and stress? These don’t disqualify you. Tinnitus and anxiety are closely linked — the brain’s threat-detection system gets entangled with the tinnitus signal, which is part of why it becomes so distressing. At Timpanogos Hearing & Tinnitus, we integrate CBT-based support and Heart Rate Variability monitoring into tinnitus care alongside Lenire for patients who need it. Treating the whole picture produces better outcomes than treating the device use alone.

Think you might be a candidate?

A comprehensive tinnitus evaluation is the first step. Timpanogos Hearing & Tinnitus offers evaluations at our American Fork and Spanish Fork locations, with South Jordan opening Summer 2026.

American Fork: (801) 763-0725 | Spanish Fork: (801) 798-7210

Schedule a Tinnitus Evaluation →

Who Should Not Use Lenire?

There are specific contraindications that are assessed during the evaluation. These include:

  • Pacemakers or other implanted electrical devices — the tongue stimulation component may interfere with device function
  • Active dental issues that would make wearing an intraoral device painful or unsafe
  • Pulsatile tinnitus — tinnitus that beats in time with your heartbeat warrants medical evaluation to identify and treat the underlying vascular or structural cause before any neuromodulation treatment is considered
  • Active Meniere’s disease — the unpredictable vertigo and fluctuating hearing thresholds in active Meniere’s require careful evaluation first
  • Tinnitus caused by a treatable underlying condition — acoustic neuroma, otosclerosis, and ototoxic medication exposure all require addressing the root cause before considering device-based treatment
  • Pregnancy — the device has not been studied in pregnant patients
  • Under age 18 — the TENT trials enrolled adults only; the approval is for adults

Not every contraindication is absolute. Patients with complex medical histories should discuss all of it with their evaluating audiologist. Many patients who assume they won’t qualify are found to be good candidates once a full evaluation is completed.

Bottom Line: Contraindications matter — but they are assessed through a clinical evaluation, not a checklist on a website. If you’re unsure whether something in your history is a problem, the answer is to book an evaluation, not to self-exclude.

What a Lenire Treatment Course Actually Looks Like

Patients need to know what they’re committing to before they say yes. Here is what the process actually looks like from the first phone call to the end of treatment.

Step 1: The Comprehensive Tinnitus Evaluation

This is not a five-minute screening. A real tinnitus evaluation — the kind performed at a tinnitus specialty practice — includes:

  • Full case history: when tinnitus started, what it sounds like, what makes it better or worse, what you’ve already tried
  • Complete audiometric testing: pure-tone thresholds, speech recognition, acoustic reflexes
  • Tinnitus matching: the evaluating audiologist characterizes the pitch and loudness of your tinnitus using audio signals, which informs device calibration
  • Validated severity questionnaires: the Tinnitus Functional Index (TFI) and Tinnitus Handicap Inventory (THI) establish your baseline
  • Contraindication screening: medications, implants, dental history, medical history
  • Psychological assessment: anxiety, depression, and sleep disruption are documented because they affect treatment planning

At Timpanogos Hearing & Tinnitus, this evaluation also includes Heart Rate Variability monitoring — an objective measure of how your nervous system is responding to tinnitus-related stress. Most practices in Utah County and the Salt Lake Valley don’t offer this. It changes what we’re able to see and plan.

Step 2: Device Setup and Calibration

If you’re a good candidate, your next appointment is device setup. The audiologist programs the sound component based on your audiometric results and calibrates the tongue stimulation to your individual comfort level. You practice using the device in the clinic before taking it home. You leave knowing exactly what to do and who to call if something doesn’t feel right.

lenire-device-timpanogos-hearing-tinnitus.jpg Alt text: The Lenire bimodal neuromodulation device — including the wireless headphones, controller unit, and Tonguetip — available at Timpanogos Hearing & Tinnitus in American Fork and Spanish Fork, Utah

Step 3: The Daily Treatment Protocol

Two 30-minute sessions every day. That’s the protocol.

Most patients do one session in the morning and one in the evening. You sit comfortably, put on the headphones, place the Tonguetip, and let the device run. The tongue stimulation feels like a mild tingling — almost everyone tolerates it easily. The device logs your session data, which is reviewed at follow-up appointments.

Step 4: The Treatment Timeline — 12 Weeks to 12 Months

This is where clinical reality differs from what trial summaries suggest.

The TENT trials used structured protocols for research purposes. In clinical practice, treatment duration ranges from 12 weeks to 12 months depending on:

  • How severe your tinnitus is at the start
  • How quickly your nervous system responds
  • Whether additional treatment components (CBT, sound therapy, hearing aids) are being used alongside Lenire
  • Whether a second course of treatment is appropriate

Some patients notice meaningful change within the first few weeks. Others don’t see significant improvement until the end of a full course or beyond. Setting realistic expectations at the start — and checking in regularly throughout — is part of what distinguishes a specialty tinnitus practice from one that hands you a device and sends you home.

What patients typically notice over time:

  • Weeks 1–4: Adjustment period. The tongue stimulation becomes comfortable and routine. Some patients notice early shifts in their tinnitus; others don’t yet.
  • Weeks 4–8: The period where most early responders begin to notice change — tinnitus may feel less intrusive, less loud, or less emotionally charged even when present.
  • Weeks 8–12+: Continued improvement in responders; outcome assessment begins toward the end of this window.
  • Beyond 12 weeks: For patients with more severe presentations or slower response, treatment continues. Outcome reassessment guides next steps.

Step 5: Outcome Assessment and Next Steps

At the conclusion of the active treatment period, a formal outcome assessment compares your TFI and THI scores to baseline. The patient’s own description of what has changed — in sleep, concentration, emotional distress, and quality of life — is part of the picture.

For patients who respond well, a monitoring plan is established. For partial responders, a second treatment course or additional intervention is discussed. For non-responders, the evaluation is revisited and alternative approaches are identified.

At Timpanogos Hearing & Tinnitus, Lenire is integrated into a broader specialty program — which may also include My Tinnitus Therapy (our proprietary digital CBT program), LACE-AI Pro auditory rehabilitation, HRV-informed treatment planning, and Real Ear Measurement-verified hearing aid fitting where indicated. The goal is not to deliver a device. It’s to achieve a durable reduction in tinnitus-related distress.

Ready to find out if Lenire is right for you?

We see patients from across the Wasatch Front — American Fork, Provo, Orem, Lehi, Salt Lake City, Murray, Sandy, Draper, South Jordan, Spanish Fork, Mapleton, Springville and Nephi. A comprehensive tinnitus evaluation is where everything starts.

American Fork: (801) 763-0725 | Spanish Fork: (801) 798-7210

Schedule Your Evaluation →

Lenire vs. Other Tinnitus Treatments

Patients researching Lenire often want to know how it stacks up against the other options they’ve encountered. Here’s an honest comparison. For the full evidence landscape, the tinnitus treatment guide goes deeper on each approach.

Tinnitus treatment comparison table showing Lenire, CBT, hearing aids, sound therapy, medications, and supplements — evidence levels and availability at Timpanogos Hearing & Tinnitus in Utah

Sound Therapy and Masking

Traditional sound therapy — white noise, nature sounds, notched music — reduces tinnitus distress by lowering the contrast between tinnitus and the acoustic environment around it. It works while you’re using it and helps many patients manage day-to-day. The TENT-A3 trial tested this directly: bimodal neuromodulation produced significantly better outcomes than sound-only therapy for patients with moderate or worse tinnitus. Sound therapy and Lenire are not competitors — they can be used together — but they are not equivalent. The mechanism is different: sound therapy manages the experience, Lenire aims to change the source. For a deeper look at how sound-based approaches compare, see does sound therapy for tinnitus really retrain your brain.

Tinnitus Retraining Therapy (TRT)

TRT combines directive counseling with low-level broadband sound enrichment. The goal is habituation — training the brain to reclassify tinnitus as a neutral signal. It has solid evidence and is a legitimate first-line option. It typically takes 18–24 months. Lenire offers a shorter, more defined treatment window with a different mechanism targeting cortical reorganization rather than habituation. Some patients complete both.

Cognitive Behavioral Therapy (CBT)

CBT is the most strongly supported psychological intervention for tinnitus, recommended by the American Academy of Otolaryngology–Head and Neck Surgery Clinical Practice Guideline. It doesn’t reduce tinnitus loudness, but it consistently reduces tinnitus-related distress, anxiety, and sleep disruption — which are often what make tinnitus truly disabling. CBT and Lenire are not alternatives. They address different dimensions of the same problem and work better together than either does alone. My Tinnitus Therapy — the proprietary digital CBT program developed exclusively by and available through Timpanogos Hearing & Tinnitus — is built into our tinnitus program for patients who need it alongside device treatment.

Hearing Aids

For patients with tinnitus and hearing loss, properly fitted hearing aids remain a first-line intervention. Restoring auditory input at affected frequencies reduces the cortical deafferentation that can worsen tinnitus. Every hearing aid fitting at Timpanogos Hearing & Tinnitus includes Real Ear Measurement verification — the clinical standard that confirms the prescription is actually reaching your ear canal. Fewer than 30% of clinics nationwide follow this standard. For patients with both hearing loss and tinnitus who qualify for Lenire, the two are used together.

Medications and Supplements

There is no FDA-approved medication for tinnitus. Antidepressants, anticonvulsants, and anxiolytics have been studied — none has demonstrated consistent efficacy for tinnitus as a primary outcome. Supplements including zinc, magnesium, and ginkgo biloba lack adequate evidence of tinnitus-specific benefit. Products marketed around binaural beats, red light therapy, and similar consumer approaches have not demonstrated clinical efficacy. For a detailed review of the medication evidence specifically, see do tinnitus medications actually work. The absence of a pharmacological option is part of why Lenire’s FDA De Novo approval represents a genuine advance — it’s the first non-medication, non-surgical option to clear that regulatory bar.

The ENT or General Audiologist Route

Many patients in Utah — in Utah County, Salt Lake County, and surrounding communities — first see their family doctor, then get referred to an ENT or a general audiology practice. This is the right path for ruling out treatable underlying causes. It is usually not where access to Lenire, comprehensive tinnitus evaluation, or CBT-based tinnitus programs exists. ENT practices with in-house audiology typically offer hearing evaluation and basic counseling. They are not set up to deliver the kind of multimodal tinnitus specialty care that a dedicated tinnitus center provides. Knowing the difference saves patients months of frustration.

When to Seek a Tinnitus Specialist

Consider a General Audiologist or ENT When…Consider a Tinnitus Specialist When…
Tinnitus is recent (under 3 months) and may resolveTinnitus has persisted more than 3 months
Tinnitus accompanied by hearing loss not yet addressedPrior hearing aids did not help tinnitus
Seeking initial evaluation to rule out medical causesTinnitus significantly disrupts sleep, work, or daily life
No prior evaluation has been completedPrior treatments have not produced meaningful improvement
Tinnitus is mild and not affecting quality of lifeInterested in Lenire or other advanced tinnitus interventions
—Tinnitus is accompanied by significant anxiety or depression
—You’ve been told your tinnitus is untreatable

How to Find a Qualified Lenire Provider

Lenire is only available through trained, certified provider clinics. There are 14 preferred provider locations in the United States. Getting to that number required completing a structured certification program — providers are not simply authorized to purchase the device and hand it to patients.

When evaluating any Lenire provider, here are the questions worth asking:

  • Does the clinic conduct a comprehensive tinnitus evaluation before recommending Lenire — or does the process skip straight to eligibility screening?
  • What validated outcome measures are used at baseline and follow-up?
  • Is psychological or CBT-based support available alongside Lenire, or is the device delivered as a standalone intervention?
  • What happens if treatment doesn’t produce the expected result?
  • Is Heart Rate Variability monitoring or any other objective assessment part of the evaluation?

The difference between a clinic that delivers a device and one that delivers a tinnitus specialty program matters most for patients with complex presentations, a history of treatment failures, or significant anxiety and sleep disruption alongside the tinnitus. For patients who have already tried hearing aids without tinnitus relief, see what to do when hearing aids don’t fix tinnitus.

Tinnitus Treatment in Northern Utah and the Salt Lake Valley

Dr. Layne Garrett performing somatic tinnitus evaluation at Timpanogos Hearing and Tinnitus clinic in Utah, assessing jaw and head movement to identify somatic tinnitus

Most patients in Utah who have chronic tinnitus have already made the rounds. They’ve seen their family doctor. They may have had a referral to an ENT. They may have tried hearing aids that helped their hearing but didn’t touch the ringing. Some have been told — more than once — that nothing can be done.

The reality in Utah County and the broader Wasatch Front is that access to comprehensive tinnitus specialty care has been limited. General audiology practices, ENT groups, and hospital-based audiology departments offer real value for hearing evaluation and basic tinnitus counseling. They are not equipped to deliver Lenire, multimodal tinnitus programs, or the kind of CBT-integrated specialty care that evidence-based tinnitus treatment requires.

Timpanogos Hearing & Tinnitus is Utah’s only full-time tinnitus specialty center and one of only 14 preferred Lenire provider clinics in the country. The practice serves patients from across the Wasatch Front — American Fork, Provo, Orem, Lehi, Pleasant Grove, Saratoga Springs, Eagle Mountain, Murray, Sandy, Draper, South Jordan, and Salt Lake City — at locations in American Fork and Spanish Fork, with a South Jordan location opening Spring 2026 to extend that access into the Salt Lake Valley.

If you have been told your tinnitus is untreatable, or if you have tried other approaches that haven’t worked, that is exactly the patient population this practice was built to serve. A 90% tinnitus success rate comes from comprehensive evaluation and a multimodal treatment approach — not from handing every patient the same device and hoping for the best.

Considering Lenire or a Comprehensive Tinnitus Evaluation?

Timpanogos Hearing & Tinnitus is one of only 14 preferred Lenire provider clinics in the United States, Utah’s only full-time tinnitus specialty center, and a founding member of the Modern Tinnitus Specialty Center network. Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP has spent more than 20 years specializing in tinnitus — with a particular focus on patients who have been told their tinnitus is untreatable, or whose prior hearing aid experiences were unsuccessful.

The practice offers comprehensive tinnitus evaluations, Lenire bimodal neuromodulation treatment, My Tinnitus Therapy (the practice’s proprietary digital CBT program), Heart Rate Variability monitoring, and Real Ear Measurement-verified hearing aid fittings.

American Fork: (801) 763-0725 | 343 S 500 E, American Fork, UT 84003 Spanish Fork: (801) 798-7210 | 642 E Kirby Lane Suite 103, Spanish Fork, UT 84660 South Jordan: Opening Spring 2026

Schedule a Tinnitus Consultation →

Frequently Asked Questions

Is Lenire FDA approved?

Yes — Lenire received FDA De Novo approval in March 2023. De Novo is a specific regulatory designation for novel devices that don’t have an existing approved predecessor. It means the FDA reviewed the clinical trial evidence — including the pivotal TENT-A3 trial published in Nature Communications — and determined that Lenire is safe and effective for the treatment of tinnitus in adults. This makes Lenire the first and only device with FDA De Novo approval specifically for tinnitus treatment.

Does Lenire cure tinnitus?

No. Lenire does not cure tinnitus, and no currently available treatment does. What the clinical trials show is that a significant proportion of patients who complete the Lenire protocol experience a clinically meaningful reduction in tinnitus severity — measured by validated instruments — and that this improvement holds at 12-month follow-up. For many patients, meaningful reduction in severity is a major quality-of-life change even when some tinnitus perception remains.

How long does Lenire treatment take?

The treatment protocol involves two 30-minute sessions per day. The length of a full treatment course ranges from 12 weeks to 12 months depending on tinnitus severity, how quickly you respond, and what other treatment components are being used alongside the device. Some patients see meaningful improvement within the first four to eight weeks. Others take longer. Setting realistic expectations at the start of treatment is part of what good clinical care looks like.

Can I buy Lenire without a prescription or online?

No. Lenire is a prescription device that requires a clinical evaluation and device calibration by a certified provider before use. It is not available through any retail or online channel. A device purchased outside of a certified provider practice would be uncalibrated and would not replicate the protocol used in clinical trials.

Does insurance cover Lenire?

Coverage varies significantly by insurer and plan. As of the date of this publication, Lenire is not broadly covered by major commercial insurers or Medicare, though this is evolving. Patients should contact their insurer directly. Financing options are available through the practice, and documentation to support insurance submissions can be provided where applicable.

Is Lenire painful?

No. The tongue stimulation produces a mild tingling sensation. Most patients find it easy to tolerate within the first few sessions. Stimulation intensity is calibrated during device setup and can be adjusted by the treating audiologist within the protocol range. In the TENT trials, no serious device-related adverse events were reported. The most common side effect was mild, temporary tingling at the tongue that resolved when sessions ended.

Can Lenire be used with hearing aids?

Yes. Lenire and properly fitted hearing aids can be used together in patients who have both tinnitus and hearing loss. They address different problems and don’t interfere with each other. For patients with significant hearing loss, addressing the hearing loss component often enhances the overall tinnitus treatment outcome.

Who should not use Lenire?

Lenire is contraindicated for patients with pacemakers or implanted electrical devices, active dental conditions that make intraoral device use impractical, pulsatile tinnitus (which requires medical evaluation first), active Meniere’s disease in the acute phase, pregnancy, and patients under 18. This is not an exhaustive list — a clinical evaluation assesses all contraindications specific to your history.

What if Lenire doesn’t work for me?

Not every patient responds, and a practice with a comprehensive tinnitus program is built to handle non-response. If you complete the protocol without meaningful benefit, the clinical team revisits your evaluation and identifies the next appropriate step — whether that’s a different treatment approach, referral for a clinical trial, or a refined combination of the elements already in use. Non-response is a clinical event that requires a response. It isn’t the end of the conversation.

How do I know if my tinnitus is serious enough for Lenire?

Tinnitus severity is measured by how much it affects your life — not by how loud it sounds. The FDA-approved indication for Lenire specifies moderate or worse tinnitus, defined as a Tinnitus Handicap Inventory score of 38 or higher. Patients with relatively quiet tinnitus can be significantly disabled by it when it disrupts sleep, concentration, relationships, and emotional health. If tinnitus is affecting your daily life in any meaningful way, it warrants a comprehensive evaluation. What you shouldn’t do is talk yourself out of seeking care because you think you’re not suffering enough.

I’ve already tried hearing aids and they didn’t fix my tinnitus. Is Lenire still an option?

Yes — and in fact, patients who have tried hearing aids without tinnitus relief are often exactly the kind of patients this practice is built for. Hearing aids address hearing loss. They don’t directly target the central auditory changes driving tinnitus in most patients. Lenire does. The two interventions are designed for different problems, and the TENT-A3 trial specifically showed that patients who don’t respond to sound-based approaches can respond to bimodal neuromodulation. An evaluation will determine whether you’re a candidate.

References & Further Reading

  1. Conlon B, Hamilton C, Meade E, et al. Different methods of delivering bimodal neuromodulation therapy for tinnitus: a head-to-head randomized trial. Science Translational Medicine. 2020;12(564):eabb2830. https://doi.org/10.1126/scitranslmed.abb2830
  2. Conlon B, Langguth B, Hamilton C, et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Scientific Reports. 2022;12:10845. https://doi.org/10.1038/s41598-022-13875-x
  3. Boedts M, Buechner A, Khoo G, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications. 2024;15:6851. https://doi.org/10.1038/s41467-024-50473-z
  4. McMahan E, Lim H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting. Communications Medicine. 2025;5:112. https://doi.org/10.1038/s43856-025-00837-3
  5. Shore SE, Roberts LE, Langguth B. Maladaptive plasticity in tinnitus — triggers, mechanisms and treatment. Nature Reviews Neurology. 2016;12(3):150–160. https://doi.org/10.1038/nrneurol.2016.12
  6. Bhatt JM, Lin HW, Bhattacharyya N. Prevalence, severity, exposures, and treatment patterns of tinnitus in the United States. JAMA Otolaryngology–Head & Neck Surgery. 2016;142(10):959–965. https://doi.org/10.1001/jamaoto.2016.1700
  7. Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. Otolaryngology–Head and Neck Surgery. 2014;151(2 Suppl):S1–S40. https://doi.org/10.1177/0194599814545325
  8. Cima RFF, Mazurek B, Haider H, et al. A multidisciplinary European guideline for tinnitus: diagnostics, assessment, and treatment. HNO. 2019;67(Suppl 1):10–42. https://doi.org/10.1007/s00106-019-0633-7
  9. Henry JA, Roberts LE, Caspary DM, Theodoroff SM, Salvi RJ. Underlying mechanisms of tinnitus: review and clinical implications. Journal of the American Academy of Audiology. 2014;25(1):5–22. https://doi.org/10.3766/jaaa.25.1.2
  10. McKenna L, Marks EM, Hallsworth CA, Schaette R. Mindfulness-based cognitive therapy as a treatment for chronic tinnitus: a randomized controlled trial. Psychotherapy and Psychosomatics. 2017;86(6):351–361. https://doi.org/10.1159/000478267
  11. U.S. Food and Drug Administration. De Novo Classification Request for the Lenire Tinnitus Treatment System. Decision Summary. March 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN220061.pdf

About the Author

Dr. Layne Garrett, Au.D., founder of Timpanogos Hearing & Tinnitus in American Fork, Utah

Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP is the founder of Timpanogos Hearing & Tinnitus, with locations in American Fork and Spanish Fork, Utah. He holds a doctorate in audiology and board certification through the American Board of Audiology, with specialty certifications in tinnitus management (CH-TM) and dementia care (CDP). Dr. Garrett has spent more than 20 years specializing in hearing loss and tinnitus—with a particular clinical focus on patients who have been told their tinnitus is untreatable, or whose prior hearing aid experiences were unsuccessful. His 90% tinnitus success rate reflects both the depth of his evaluation protocols and a comprehensive, multimodal treatment approach that most general audiology practices do not offer. Timpanogos Hearing & Tinnitus is one of only 14 preferred provider clinics for Lenire bimodal neuromodulation therapy in the United States, among the first clinics in the country to integrate Heart Rate Variability monitoring into tinnitus treatment, and an early adopter of LACE-AI Pro auditory rehabilitation protocols. Every hearing aid fitting at Timpanogos Hearing & Tinnitus includes Real Ear Measurement verification—a standard performed by fewer than 30% of clinics nationwide. Dr. Garrett participates in humanitarian audiology missions through Hearing the Call and operates a local program providing hearing aids at no cost to qualifying Utah residents earning below 250% of the federal poverty level. Timpanogos Hearing & Tinnitus has also established a partnership with Bingham Family Clinic to expand access to evidence-based hearing care for underserved patients across the Wasatch Front. He produces regular educational content on audiology, tinnitus, cognitive hearing health, and emerging treatments to help patients and families make fully informed decisions.

Date Reviewed/Last Modified: April 6, 2026 9:00 AM MDT

Similar Posts